Peptide Library / Detail
Cotadutide
Half-life
Approximately 7 days (extended through depot formulation)
Delivery
Subcutaneous injection
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
Cotadutide is a dual agonist peptide that simultaneously activates both glucagon-like peptide-1 (GLP-1) and glucagon receptors. It was developed for the treatment of type 2 diabetes, obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD). This dual-action peptide combines the glucose-lowering and appetite-suppressing effects of GLP-1 agonism with the metabolic and energy expenditure benefits of glucagon receptor activation.
Usage
Cotadutide is administered via subcutaneous injection, typically on a weekly basis due to its extended half-life formulation. Clinical trials have evaluated various dosing regimens, with research protocols examining doses ranging from lower therapeutic levels to optimized maintenance doses. The peptide utilizes self-assembly technology to create a long-acting depot formulation with controlled release properties.
Mechanism of Action
Cotadutide works through dual receptor agonism: it activates GLP-1 receptors to enhance insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite, while simultaneously activating glucagon receptors to increase energy expenditure, promote lipolysis, and reduce hepatic steatosis. This balanced dual mechanism helps restore insulin sensitivity, preserve pancreatic β-cell function, and dissipate liver fat accumulation. The peptide's pharmacokinetic profile follows therapeutic peptide principles with sustained systemic exposure through controlled-release depot technology.
Benefits(7)
- Significant reduction in HbA1c and improved glycemic control in type 2 diabetes
- Substantial weight loss through combined appetite suppression and increased energy expenditure
- Reduction of hepatic steatosis and improvement in fatty liver disease
- Restoration of insulin sensitivity in metabolic tissues
- Preservation and rescue of pancreatic β-cell function
- Potential benefits for chronic kidney disease in diabetic patients
- Favorable cardiometabolic effects across the metabolic syndrome spectrum
Side Effects(6)
- Gastrointestinal symptoms including nausea and vomiting
- Diarrhea and abdominal discomfort
- Reduced appetite and early satiety
- Potential injection site reactions
- Mild transient increases in heart rate
- Headache and fatigue